Human medicines European public assessment report (EPAR): Soliris, eculizumab, Hemoglobinuria, Paroxysmal, Date of authorisation: 20/06/2007, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene), thalidomide, Multiple Myeloma, Date of authorisation: 16/04/2008, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 21/04/2021, Revision: 6, Status: Authorised

Antimicrobial resistance in veterinary medicine

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, COVID-19 virus infection, Date of authorisation: 25/03/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging;Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Pylclari, piflufolastat (18F), Prostatic Neoplasms, Date of authorisation: 24/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma;Urticaria, Date of authorisation: 25/10/2005, Revision: 48, Status: Authorised

ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010649/202302

ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : List of nationally authorised medicinal products - PSUSA/00010649/202302